Mesa Laboratories Stock MLAB
Mesa Laboratories designs, manufactures, and distributes quality control products and services for highly regulated industries. Mesa Laboratories stock (MLAB): Quarterly and annual results since 2024 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Mesa Laboratories stock (MLAB): listed on Nasdaq, index Russell 2000. NadirAlpha has evaluated 46 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Revenue Q1 FY2027 (Apr to Jun 2026): USD 60 million (+1% year on year). Latest reported (Q1 FY2027 (Apr to Jun 2026)): Total Net Leverage Ratio. Latest reading: Operating income doubled, Net income turned positive, Margin expanding, Operational disruption, Strategic pivot, Revenue accelerating.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Mesa Laboratories Current Status
Summary of the most recent reporting period of Mesa Laboratories (Q1 FY2027): core figures, drivers and management statements, every figure with a source number. NadirAlpha methodology
Assessment by NadirAlpha, as of Q1 FY2027 (Apr to Jun 2026).
“I joined Mesa about one hundred days ago. I did not spend my time writing a vision statement, I spent it inside the company, with our people and our customers. What I found is a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix. My focus is disciplined execution and consistent, profitable growth across our four divisions. In November, alongside first-half results, I will give full-year guidance.”
“We remain focused on disciplined capital allocation and preserving the financial flexibility necessary to support Mesa's strategic priorities.”
Mesa Laboratories Stock: Key Figures ($ million)
NadirAlpha shows fiscal years, half-years and quarters of Mesa Laboratories one below the other, most recently Q1 FY2027; every figure is clickable and leads to raw value, location and source. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Calendar quarter | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | OCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2026 | Q2/2025–Q1/2026 | 249.1 | 18.5 | 63.49 | 6.7 | 1.21 | 42.8 | 29 |
| FY2025 | Q2/2024–Q1/2025 | 241 | 16.3 | 54.01 | -2 | -0.36 | 46.8 | 25 |
| FY2024 | Q2/2023–Q1/2024 | 216.2 | -272.1 | 50.51 | -254.2 | -47.20 | 44.1 | 21 |
Quarters
| Period | Calendar quarter | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-Q1* | Q2/2026 | 2026-08-10 | 60.1 | 7 | 15 | 2.8 | 0.49 | 14.2 | 30.7 | 35.4~ | 15 |
| 2026-Q4* | Q1/2026 | 2026-05-27 | 63.7 | 2.7 | 18.3 | -4.1 | -0.75~ | 13.5 | 26.9 | 40.6 | 129 |
| 2026-Q3* | Q4/2025 | 2026-02-03 | 65.1 | 8 | 17.1 | 3.6 | 0.65 | 18 | 29 | 39.5 | 13 |
| 2026-Q2* | Q3/2025 | 2025-11-06 | 60.7 | 4.7 | 15.2 | 2.5 | 0.45 | 7.1 | 20.4 | 49 | 12 |
| 2026-Q1* | Q2/2025 | 2025-08-05 | 59.5 | 3.1 | 12.9 | 4.7 | 0.85 | 0.9 | 21.3 | 146.5 | 11 |
| 2025-Q4* | Q1/2025 | 2025-05-28 | 62.1 | 1.5 | 12.3 | -7.1 | -1.31~ | 11.9 | 27.3 | 141.2 | 10 |
| 2025-Q3* | Q4/2024 | 2025-02-04 | 62.8 | 5.8 | 14.5 | -1.7 | -0.31 | 17.3 | 27.3 | 142.2 | 9 |
| 2025-Q2* | Q3/2024 | 2024-11-07 | 57.8 | 3.5 | 14.4 | 3.4 | 0.63 | 3.5 | 24.3 | 145.8 | 8 |
| 2025-Q1* | Q2/2024 | 2024-08-05 | 58.2 | 5.6 | 14 | 3.4 | 0.62 | 9.9 | 28.5 | 45.6~ | 7 |
| 2024-Q4* | Q1/2024 | 2024-06-05 | 58.9 | -271.3 | 12.3 | -254.6~ | -47.26*≈ | 12.3 | 28.2 | – | 21 |
| 2024-Q3* | Q4/2023 | 2024-02-05 | 53.5 | -0.1 | 12 | 2.1 | 0.39 | 10.4 | 28.2 | – | 5 |
| 2024-Q2* | Q3/2023 | 2023-11-06 | 53.2 | -0.1 | 10.3 | -1.2 | -0.23 | 9.1 | 35.6 | – | 4 |
| 2024-Q1* | Q2/2023 | 2023-08-03 | 50.6 | -0.7 | 10.4 | -0.5 | -0.10 | 9.7 | 32.4 | – | 3 |
Mesa Laboratories Balance Sheet & Cash Flow ($ million)
Balance sheet and cash flow of Mesa Laboratories up to Q1 FY2027 in $ million: net debt = financial debt minus cash, free cash flow = operating cash flow minus capex, every input sourced. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Calendar quarter | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 | Q2/2025–Q1/2026 | 2026-05-27 | 26.9 | 67.5 | 40.6 | 23.3 | 42.8 | 3.2 | 39.6 | 29 |
| FY2025 | Q2/2024–Q1/2025 | 2025-05-28 | 27.3 | 168.5 | 141.2 | 24.5 | 46.8 | 4.2 | 42.6 | 10 |
| FY2024 | Q2/2023–Q1/2024 | 2024-06-28 | 28.2 | – | – | 31.6 | 44.1 | 2.6 | 41.6 | 6 |
Quarters
| Period | Calendar quarter | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2027-Q1 | Q2/2026 | 2026-08-10 | 30.7 | 66.1~ | 35.4~ | 5.6 | 14.7 | 0.6 | 14.2 | 15 |
| 2026-Q4 | Q1/2026 | 2026-05-27 | 26.9 | 67.5 | 40.6 | 5.8 | 14 | 0.4 | 13.5 | 129 |
| 2026-Q3 | Q4/2025 | 2026-02-03 | 29 | 68.4 | 39.5 | 5.7 | 18.8 | 0.7 | 18 | 13 |
| 2026-Q2 | Q3/2025 | 2025-11-06 | 20.4 | 69.4 | 49 | 5.8 | 8.2 | 1.1 | 7.1 | 12 |
| 2026-Q1 | Q2/2025 | 2025-08-05 | 21.3 | 167.7 | 146.5 | 6 | 1.9 | 1 | 0.9 | 11 |
| 2025-Q4 | Q1/2025 | 2026-05-27 | 27.3 | 168.5 | 141.2 | 7.5 | 12.7 | 0.8 | 11.9 | 129 |
| 2025-Q3 | Q4/2024 | 2025-02-04 | 27.3 | 169.5 | 142.2 | 5.5 | 18.1 | 0.8 | 17.3 | 9 |
| 2025-Q2 | Q3/2024 | 2024-11-07 | 24.3 | 170.2 | 145.8 | 6.1 | 5.3 | 1.8 | 3.5 | 8 |
| 2025-Q1 | Q2/2024 | 2024-08-05 | 28.5 | 74.1~ | 45.6~ | 5.5 | 10.7 | 0.9 | 9.9 | 7 |
| 2024-Q4 | Q1/2024 | 2025-05-28 | 28.2 | – | – | 6.3 | 12.9 | 0.5 | 12.3 | 10 |
| 2024-Q3 | Q4/2023 | 2024-02-05 | 28.2 | – | – | 9 | 11.5 | 1.1 | 10.4 | 5 |
| 2024-Q2 | Q3/2023 | 2023-11-06 | 35.6 | – | – | 8.1 | 9.8 | 0.6 | 9.1 | 4 |
| 2024-Q1 | Q2/2023 | 2023-08-03 | 32.4 | – | – | 8.1 | 9.9 | 0.3 | 9.7 | 3 |
Mesa Laboratories Guidance Tracking (latest per metric/period · 1/1)
NadirAlpha records 1 guidance statements of Mesa Laboratories neutrally: annual and quarterly targets, direction of change and outcome as a dot with legend, with no estimate of our own. NadirAlpha methodology
Direction: confirmed Verdict: pending
| For period | Guided on | Metric | Guided | Verdict | Direction | Source |
|---|---|---|---|---|---|---|
| 2026-H1 | 2025-08-05 | Revenue | meet revenue goals | 26 |
Mesa Laboratories Stock: Price & Chart
Price history of Mesa Laboratories stock (MLAB) as a TradingView chart, loaded only after a click, alongside the trend of the key figures from the tables. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Mesa Laboratories Event Timeline
What happened at Mesa Laboratories since 2024: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology
2027 · 7 events
“As announced in March, I am in the middle of my onboarding journey as I am conducting my first 100 days review of the businesses since joining Mesa on April 13. I want to share that I am even more excited today than the day I joined. The Mesa diversified platform has tremendous potential to create shareholder value while delivering on our promise to Protect the Vulnerable. Upon completion of my 100-day review of our business, I am looking forward to begin meeting with our shareholders and discussing my vision for the Company moving forward. I also expect to be in position to provide rest of the year guidance along with the release of H1 results.”
Sterilization and Disinfection Control revenue declined 3.6% organically due to fulfillment and delivery execution challenges impacting customer shipments 30
Operating income increased 129.5% to 7 million from $3.1 million in the prior-year quarter, driven by operating efficiencies and cost-containment initiatives 15
Operating income more than doubled YoY (3.1 to USD 7.0 million, +126%). 15
Total revenues increased 1.0% to 60.1 million; core organic revenue growth returned to positive at 0.4% 30
Full-year net income of $6.7M versus prior-year loss of $1.9M; 440% increase; diluted EPS $1.21 29 14
Non-GAAP AOI margin expanded 200bps to 25.5% of revenues; consolidated gross profit margin improved 0.9pp to 63.5% 29 14
Siddhartha Kadia appointed President and CEO effective April 13, 2026, initiating 100-day business review 29
2026 · 14 events
Net income turned positive for the first time after 2 negative fiscal years (-2.0 to +USD 6.7 million). 29
“While macro conditions in the first three quarters of FY26 were challenging, we remain encouraged that end markets are stabilizing, our innovative solutions remain top of mind with customers, and our highly adaptable operating model and team will enable us to further accelerate both top and bottom-line growth as market conditions improve”
Net income of $3.6M versus prior-year Q3 loss of $1.7M; operating income increased 38.0% to $8.0M 13 28
Biopharmaceutical Development revenues grew 17.5% organically driven by higher Immunoassays and Peptides volumes 13 28
Consolidated gross profit margin improved to 64.2% from 63.3% in prior-year Q3; Clinical Genomics gross margin improved to 60.5% despite lower revenues 13
“While the first half of FY26 was full of many challenges, we are encouraged by the faith that our customers place in our solutions and team, our traction with key initiatives, the demonstrated strength of our operating model, and the resilience of our team”
Consolidated revenues grew 5.0% to $60.7M with 3.7% core organic growth; Biopharmaceutical Development consumables revenues up approximately 14% 12 27
Clinical Genomics China revenues contracted approximately 58% due to macroeconomic, tariff, and regulatory headwinds; continued decreases expected for remainder of fiscal year 27
“While 1Q26 was challenging in the face of a difficult macroeconomic environment, we are encouraged by our continuing commercial success, traction with key initiatives, and the resilience of our operating model”
“We were pleased to realize several important strategic milestones during FY25 including: 1) exceeding our acquisition commitment for the first twelve months of full ownership of GKE for both revenues and profitability, 2) fully integrating GKE into our corporate infrastructure within nine months, 3) launching Veridose 2.0 in the CG division, our most comprehensive PGx panel to date, 4) implementing Salesforce CRM across the sales teams in all four divisions, 5) gaining solid traction with our Commercial Excellence initiatives as evidenced by accelerated bookings growth, and 6) accelerating traction with the Mesa Way by completing 45 discrete process improvement events, a new Mesa record”
Clinical Genomics revenues fell 9.7% (10.7% core organic decline) on $1.8M China revenue contraction (69% decline) due to macroeconomic and regulatory uncertainty 11 26
Net income turned positive for the first time after 2 negative periods (-7.1 to +USD 4.7 million). 11
Gross profit margin declined 2.0pp to 62.0%; AOI margin fell to 21.7% from 26.4%, driven by tariff charges and FX impacts 11 26
Sterilization and Disinfection Control revenues grew 10.7% with 7.5% core organic growth via strong commercial execution 11 26
Full-year operating income improved to $16.3M; prior year included a $274.5M impairment loss (base effect), adjusted operating income grew 12.3% for the year 10 25
Full-year revenues rose 11.5% to $241.0M with 5.0% core organic growth; all four divisions delivered core organic revenue growth in Q4 FY2025 for the first time in the fiscal year 25
GKE acquisition fully integrated within nine months; contributed $24.8M revenues in FY2025 and exceeded initial revenue and profitability commitments 25
2025 · 10 events
Operating income turned positive for the first time after 1 negative fiscal year (-272.1 to +USD 16.3 million). 25
“Profitability for the quarter as measured by our primary metric of AOI excluding unusual items grew by 13.3% versus the prior year to $14,788. Versus prior year, gross profit percentage expanded by 80 bps but shrank by 240 bps when excluding the impact of non-cash charges. The contraction was primarily due to both product and geographical mix.”
Operating income improved to $5.8M in Q3 from a loss of $67K in Q3 FY2024; adjusted operating income grew 13.3% to $14.8M with 23.5% margin 24
Revenues increased 17.5% to $62.8M in Q3 with core organic growth of 13.2%; Biopharmaceutical Development grew 31.3% organically and Calibration Solutions grew 18.9% organically 24
“Profitability as measured by our primary metric of AOI excluding unusual items grew by 18.9% versus the prior year to $14,352, a 210 bps expansion when expressed as a percentage of revenue. Versus prior year, gross profit percentage expanded by 90 bps but shrank by 40 bps when excluding the impact of non-cash charges primarily due to mix.”
Operating income reached $3.5M in Q2 versus a loss of $60K in the prior year quarter; non-GAAP adjusted operating margin expanded 210 basis points to 24.8% of revenues 23
Biopharmaceutical Development revenues increased 28.9% in Q2 driven by increased capital equipment spending in North America and Europe; core organic growth of 27.9% 23
Clinical Genomics revenues declined 26.0% in Q2 due to China economic slowdown and U.S. regulatory challenges on lab-developed tests; core organic decline of 26.5% 8
“Looking forward, we are hopeful that our biopharmaceutical related end markets will continue the strength exhibited in 4Q24 and 1Q25. In any market scenario we will work diligently so that our differentiated products, strategic initiatives and the Mesa Way operating model enable us to outperform,”
Operating income improved to $5.6M in Q1 from a loss of $664K in the prior year quarter; adjusted operating income rose 47% to $15.3M or 26.4% of revenues 22
Total revenues rose 14.9% to $58.2M in Q1; GKE contributed 12.4% inorganic growth and core organic growth was 2.5%, led by 21.4% organic growth in Biopharmaceutical Development 22
Gross profit margin expanded 250 basis points to 64.0% in Q1; excluding non-cash charges, expansion was 150 basis points 22
2024 · 13 events
“Annual revenues of $216,187 decreased by 1.3% versus the prior year, driven by a decline in core organic revenues of 5.4%, partially offset by GKE revenues of $9,289. Core organic headwinds were primarily in BPD and CG which offset growth in both SDC and CS. Specifically, BPD faced the softening of demand for capital equipment in the biopharmaceutical vertical, while CG incurred headwinds from the previously announced loss of Sema4 as a customer at the end of the second quarter in FY23 and the ongoing impact of the economic slowdown in China,”
Recorded $274.5 million non-cash impairment on goodwill and long-lived assets: $236.4 million in Clinical Genomics and $38.2 million in Biopharmaceutical Development divisions, driving FY2024 GAAP net loss of $254.2 million (21, 6)
Q4 revenues increased 6% to $58.9 million, with headline growth driven by GKE contribution of $5.5 million; core organic revenues declined 3.5% (21)
Clinical Genomics division restructured under new General Manager; 17 positions eliminated with expected annual savings of approximately $3.0 million; updated business strategy implemented (21)
“We were pleased to add GKE to our Sterilization & Disinfection Control division as their high-quality chemical indicators and healthcare channels are highly complementary to our traditional strengths in biological indicators and life science channels. Looking ahead, with ongoing economic uncertainty, we will be conservative in deploying any increases in operating expenses.”
Organic revenues declined 8.6%; Clinical Genomics down 19.5% driven by China economic slowdown and healthcare anti-corruption initiatives; Biopharmaceutical Development down 19.1% on constrained capital equipment placements (20)
Calibration Solutions organic revenue growth of 12.9% with gross margin expansion of 600 basis points as prior-year supply chain constraints continued to abate (20)
Net income turned positive for the first time after 2 negative periods (-1.2 to +USD 2.1 million). 5
“profitability for 2Q24, as measured by our primary metric of adjusted operating income excluding unusual items was $11,163, a decrease of 29.1% quarter over quarter primarily due to the decreased revenues. This number however did increase by 17.2% sequentially from 1Q24 primarily due to increases in revenues. Additionally, during 2Q24 we implemented cost control actions taken in response to the unclear macroeconomic environment and the specific slow-down in the biopharmaceutical vertical which are expected to generate annual savings of approximately $2,000 starting in 3Q24.”
Revenues declined 9.5% to $53.2 million; core organic down 10.1%, with approximately $8.2 million annual headwind from prior-year Sema4 customer loss in Clinical Genomics and continued softening in capital equipment demand (19)
Clinical Genomics gross margin declined 800 basis points to 49.7%, falling below long-term target of high 50s to low 60s, on lower revenue absorption following Sema4 loss (19)
GKE acquisition completed October 2023, expanding Sterilization and Disinfection Control with chemical sterilization indicators and biologics portfolio; credit facility expanded from $75 million to $125 million to partially fund the deal (4)
“We are pleased to see our Calibration Solutions division return to growth as our supply chain issues abate, that the Clinical Genomics business systems pipeline continues to grow in North America, and that our overall business in China remains robust. Given ongoing economic uncertainty, we will be conservative in deploying operating expenses.”
Operating loss improved 85.5% to $(664) thousand from $(4,594) thousand, primarily due to resolution of prior-year labor shortages and supply chain difficulties in Calibration Solutions and Sterilization and Disinfection Control (18)
Calibration Solutions revenues +12%, driven by abatement of prior-year supply chain disruptions and labor shortages that had constrained production (3)
Biopharmaceutical Development organic decline of 10.3% on softening demand for capital equipment; segment viewed as unlikely to grow at historical rates in FY2024 (3)
Full-year gross profit margin expanded 2 percentage points to 61%; prior-year FY2022 base included $7.5M Agena acquisition inventory step-up charge that did not recur, partially offset by unfavorable product mix and adverse foreign currency 2
Mesa Laboratories Business Model
How Mesa Laboratories (MLAB) makes its money, summarised from the filings up to Q1 FY2027, neutral and without forecast. NadirAlpha methodology
Mesa Laboratories designs, manufactures, and distributes quality control products and services for highly regulated industries. The company operates through four reporting divisions: Sterilization and Disinfection Control, which produces biological and chemical indicators used to validate sterilization processes in healthcare and pharmaceutical settings; Calibration Solutions, which provides calibration instruments and associated services; Biopharmaceutical Development, offering immunoassay and analytical tools for biopharmaceutical research customers; and Clinical Genomics, which supplies molecular diagnostic products for clinical laboratory use. Revenue is generated through the sale of instruments, consumable products, and service contracts across these divisions, with a customer base spanning life sciences, healthcare, pharmaceutical manufacturing, and industrial sectors. The Biopharmaceutical Development segment carries a structural cost-currency mismatch, as expenses are incurred in Swedish Krona while revenues are generated predominantly in USD and EUR.
Mesa Laboratories Stock: Share-Price Drivers
Factors Mesa Laboratories itself names as material for its business development, reproduced neutrally, without price forecast and without assessment of our own. NadirAlpha methodology
Mesa's Sterilization and Disinfection Control unit is the largest of the four reportable segments, at 24.5 million in revenue in 2027-Q1 ahead of Calibration Solutions, Biopharmaceutical Development and Clinical Genomics, so its direction sets the pace for group revenue of 60.1 million 30
Mesa's largest segment generated 24.5 million of revenue in 2027-Q1, higher by 3.6%; the GKE acquisition and the company's pursuit of 510(k) clearance for the US market broaden the sterilization offering 30 14
Mesa reported 13.3 million of Calibration Solutions revenue in 2027-Q1, up 7.6% and the fastest-growing of the four segments 30
Mesa booked 12.1 million of Biopharmaceutical Development revenue in 2027-Q1, higher by 5.0% 30
Mesa's Clinical Genomics revenue was broadly flat at 10.3 million in 2027-Q1, up 0.1%; the division is running the Breakthrough 7 strategic plan and launched Veridose 2.0 to regain traction, with the outcome not yet evident in the segment line 30 26 25
Mesa's net debt fell to 35.4 million in 2027-Q1 from 146.5 million a year earlier, following the Convertible Senior Notes settlement in August 2025 14
Mesa's adjusted operating income reached 15 million in 2027-Q1 against 12.9 million a year earlier, with reported operating income of 7 million 30
Sector trend: Mesa's group revenue of 60.1 million carried a gross margin of 64.9% in the latest quarter, with underlying demand broadly stable to higher across the sterilization, calibration and biopharmaceutical end-markets 15 30. Within that mix the company's Calibration Solutions and Biopharmaceutical Development lines are growing faster than the larger Sterilization and Disinfection Control franchise, while Clinical Genomics is roughly flat 30.
Mesa Laboratories Revenue by Type (as of 2027-Q1 · USD million · 5/6)
The segments of Mesa Laboratories in the company's own definition, each row with its basis (3, 6 or 12 months), rows in grey are no longer reported separately. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|
| Period 2027-Q1 (3M) | |||||
| Sterilization and Disinfection Control | FY2022 | 24.5 | 3.6% | – | 30 |
| Calibration Solutions | FY2022 | 13.3 | 7.6% | – | 30 |
| Biopharmaceutical Development | FY2022 | 12.1 | 5% | – | 30 |
| Clinical Genomics | FY2022 | 10.3 | 0.1% | – | 30 |
| Total | 2026-Q1 | 60.1 | 1% | 64.9% | 15 |
| Period 2025-Q3 (9M) | |||||
| Mesa's reportable segments | 2023-Q1 | 178.8 | 4.3% | 62.9% | 9 |
Mesa Laboratories Products & announcements (3/10 active+recent)
10 product announcements of Mesa Laboratories since 2024, grouped by year; active means still mentioned in the most recent reports, nothing is deleted. NadirAlpha methodology
Status: PlannedLaunched
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2026 | |||
| New Product Development acceleration in Clinical Genomics | 2026-03 | 26 | |
| Peptide system export controls | 2026 | 29 | |
| GKE 510(k) regulatory clearance pursuit for US market | 2026 | 14 | |
| 2025 | |||
| Clinical Genomics division strategic plan deployment (Breakthrough 7) | 2025-05 | 26 | |
| Veridose 2.0 launch in Clinical Genomics division | 2025 | 25 | |
| Salesforce CRM implementation across sales teams | 2025 | 25 | |
| 2024 | |||
| 510(k) clearance for certain GKE products in United States (3x) | 2024-09 | 10 | |
| FDA regulatory approval for certain GKE products for U.S. sale | 2024 | 6 | |
| 2023 | |||
| Class III IVD panel approval - pharmacogenetics (4x) | 2023-01 | 2 | |
| PurePep EasyClean products launch | 2023 | 2 | |
Mesa Laboratories Transactions & Events (8)
Transactions of Mesa Laboratories since 2024: acquisitions, disposals, agreements and regulation, deliberately including smaller items; purchase prices only when the company names them. NadirAlpha methodology
Acquisitions by Mesa Laboratories
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2024 | |||
| 2025 Notes repurchase | 2024-04 | Completed | 6 |
| Belyntic contingent consideration (2x) | 2024-03 | Completed | 8 |
| 2023 | |||
| GKE acquisition (4x) | 2023-10 | Completed | 11 |
| GKE GmbH, SAL GmbH and Beijing GKE Science & Technology Co. Ltd. acquisition (2x) | 2023-10 | Completed | 14 |
| 2022 | |||
| Belyntic peptide purification business acquisition | 2022-11 | Completed | 6 |
| Belyntic acquisition | 2022-10 | Completed | 2 |
| 2021 | |||
| Agena acquisition (2x) | 2021-10 | Completed | 2 |
Divestitures and exits by Mesa Laboratories
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2022 | |||
| Sema4 expanded carrier screening closure (2x) | 2022-10 | Divested | 19 |
Mesa Laboratories Risks (69 since the annual report of 2026-06-03, 208 tracked in total)
Which risks Mesa Laboratories has named since the annual report, company-specific first, generic standard risks in the expandable part; first mention refers to the document base from 2023. NadirAlpha methodology
Category: CustomersSupply chainGeopoliticsCompetitionRegulatoryMacroFinancialLegalPeopleTechnologyCyberMarketStrategyESG
| Risk | Category | Last reported |
|---|---|---|
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2026-08-10 (2027-Q1), source 30 | ||
| Continued revenue weakness in China market, particularly Clinical Genomics | = | |
| Fulfillment and delivery execution challenges in Sterilization and Disinfection Control | = | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2026-08-10 (2027-Q1), source 15 | ||
| Foreign currency exchange rate fluctuations affect reported revenue and operating results. | = | |
| Price competition affects gross profit margins and ability to pass cost increases to customers. | = | |
| Mesa Laboratories: first mention in 10-K annual report of 2026-06-03 (FY2026), source 14 | ||
| Tariff impositions and trade policy changes may impact costs and pricing strategies. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2025-11-06 (2026-Q2), source 12 | ||
| Supply chain challenges and cost pressures impact gross profit and operational efficiency. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2025-08-05 (2026-Q1), source 11 | ||
| Macroeconomic uncertainty and tariff conditions affecting customer purchasing decisions | 2027-Q1 2026-08-10 30 | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2024-11-07 (2025-Q2), source 8 | ||
| Higher interest rate borrowings under Credit Facility replace lower-cost Notes. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2024-08-05 (2025-Q1), source 22 | ||
| Foreign currency exchange rate fluctuations | 2027-Q1 2026-08-10 30 | |
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2024-06-05 (FY2024), source 21 | ||
| Global economic conditions and customer capital spending trends affect organic revenue growth. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2023-11-06 (2024-Q2), source 19 | ||
| Laws regulating fraud and abuse in healthcare industry and privacy regulations | 2027-Q1 2026-08-10 30 | |
| Mesa Laboratories: first mention in 10-K annual report of 2023-05-30 (FY2023), source 2 | ||
| Outstanding legal proceedings and contingent liabilities including legal settlement | 2027-Q1 2026-08-10 30 | |
| Product liability claims and litigation risks in medical device and pharmaceutical industries. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2023-02-06 (2023-Q3), source 1 | ||
| Pharmaceutical, healthcare and medical device industries concentration; customer capital spending volatility. | 2027-Q1 2026-08-10 15 | |
| Mesa Laboratories: first mention in 10-K annual report of 2026-06-03 (FY2026), source 14 | ||
| Ongoing audits by tax authorities could result in additional tax payments or unfavorable adjustments. | = | |
| Clinical Genomics division materially impacted by macroeconomic uncertainty and trade tensions in China. | = | |
| Tariffs reduce gross margins; tariff mitigation through increased inventory carries working capital costs. | = | |
| CEO transition announced in March 2026 effective April 2026 may cause management disruption. | = | |
| Technological advancements in dialysis machines may decrease demand for renal care products. | = | |
| Additional jurisdictions could require collection and remittance of sales taxes. | = | |
| Biopharmaceutical Development incurs expenses in Swedish Krona while revenues mostly in USD/EUR. | = | |
| Cyberattacks or data breaches could disrupt operations and harm reputation. | = | |
| Future acquisitions may require financing on unfavorable terms or result in equity dilution. | = | |
| Inability to manage growth or implement efficiency initiatives could affect operating results. | = | |
| Military conflicts and disruptions to global trade routes could adversely impact macroeconomic conditions. | = | |
| Tariffs and trade restrictions may increase costs and disrupt supply chains. | = | |
| Disruptions in supply chains or sole-source supplier reliance could interrupt production. | = | |
| Catastrophic events could disrupt operations and cause significant losses. | = | |
| Healthcare industry cost-containment initiatives may reduce demand for products. | = | |
| Loss of key personnel or inability to hire qualified employees could materially adversely affect business. | = | |
| Employee or agent misconduct could result in penalties and reputational harm. | = | |
| Manufacturing defects or regulatory non-compliance could result in recalls and reputational harm. | = | |
| EU Cyber Resilience Act compliance may require product modifications and increase costs. | = | |
| Lengthy and uncertain regulatory approval processes could delay product introductions. | = | |
| Changes in tax laws including multinational taxation rules could adversely affect tax position. | = | |
| Inability to consummate acquisitions at historical rates could negatively impact growth. | = | |
| Ineffective deployment of AI or failure to keep pace with competitors could affect competitiveness. | = | |
| Competitors with larger resources may reduce demand and force pricing concessions. | = | |
| Ability to increase prices may be limited by competitive pressure on sales volumes. | = | |
| Industry consolidation could increase reliance on fewer, larger customers or suppliers. | = | |
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2026-05-27 (FY2026), source 29 | ||
| Significant contraction in China revenues of $5.2 million representing 57.4% decline | = | |
| U.S. government actions including changes in trade policies and medical device regulations | = | |
| Outstanding claims, legal proceedings, tax audits and assessments | = | |
| Laws regulating fraud and abuse in healthcare and privacy of health information | = | |
| Mesa Laboratories: first mention in 10-K annual report of 2025-05-28 (FY2025), source 10 | ||
| Failure to maintain appropriate corporate responsibility practices could harm reputation. | FY2026 2026-06-03 14 | |
| Product modifications may require new clearances or product recalls. | FY2026 2026-06-03 14 | |
| Mesa Laboratories: first mention in 8-K-EX99.1 earnings release of 2024-08-05 (2025-Q1), source 22 | ||
| Market acceptance of company products and enhanced or new products | FY2026 2026-05-27 29 | |
| Various contingent liabilities and legal proceedings risk factors per SEC filings | 2026-Q3 2026-02-03 28 | |
| Mesa Laboratories: first mention in 10-K annual report of 2024-06-28 (FY2024), source 6 | ||
| Significant debt obligations require substantial cash flow; default could materially adversely affect business. | FY2026 2026-06-03 14 | |
| Material weaknesses in internal controls could impair financial reporting and investor confidence. | FY2026 2026-06-03 14 | |
| Adverse changes in distributor relationships or financial condition may adversely affect business. | FY2026 2026-06-03 14 | |
| Trading price of common stock may be volatile and subject to securities litigation. | FY2026 2026-06-03 14 | |
| Inadequate intellectual property protection could result in competitive injury. | FY2026 2026-06-03 14 | |
| Indemnification provisions may not fully protect against acquisition-related liabilities. | FY2026 2026-06-03 14 | |
| Inability to introduce and commercialize new products may adversely affect growth. | FY2026 2026-06-03 14 | |
| Mesa Laboratories: first mention in 10-K annual report of 2023-05-30 (FY2023), source 2 | ||
| Goodwill and intangible assets of $270.2 million may require impairment losses. | FY2026 2026-06-03 14 | |
| Climate change risks and regulatory requirements may increase costs and disrupt operations. | FY2026 2026-06-03 14 | |
| Additional stock issuances could result in substantial dilution to shareholders. | FY2026 2026-06-03 14 | |
| Inflation increases labor, materials and freight costs; ability to recover through pricing uncertain. | FY2026 2026-06-03 14 | |
| Elevated interest rates, inflation, reduced capital spending, and labor constraints may adversely affect business. | FY2026 2026-06-03 14 | |
| Decline or lower-than-expected growth in served markets could reduce demand for products and services. | FY2026 2026-06-03 14 | |
| Company relies on equity-based compensation to recruit and retain employees. | FY2026 2026-06-03 14 | |
| Violations of data privacy laws could result in fines and reputational harm. | FY2026 2026-06-03 14 | |
| Export control violations could result in fines and loss of market access. | FY2026 2026-06-03 14 | |
| Non-compliance with government contract requirements could result in penalties or debarment. | FY2026 2026-06-03 14 | |
| Marketing for off-label uses could result in substantial penalties and enforcement actions. | FY2026 2026-06-03 14 | |
| Changes in regulations could reduce demand or increase compliance costs. | FY2026 2026-06-03 14 | |
| Non-compliance with regulations could result in fines, penalties, and product withdrawals. | FY2026 2026-06-03 14 | |
| Mesa Laboratories: first mention in 10-Q quarterly report of 2023-02-06 (2023-Q3), source 1 | ||
| Variable rate debt exposes company to interest rate risk and increased borrowing costs. | FY2026 2026-06-03 14 | |
Mesa Laboratories Reported KPIs (as disclosed) (131)
The story KPIs of Mesa Laboratories that standard databases usually miss, grouped by publication, most recent first, with source number. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| Mesa Laboratories, published 2026-08-10, period 2027-Q1 | ||
| working capital | 45.5 | 15 |
| revolver outstanding | 77.3 | 15 |
| revolver borrowing capacity | 125.0 | 15 |
| required principal debt payments 12m | 5.6 | 15 |
| expected cash interest expense 12m | 7.9 | 15 |
| dividend per share | 0.16 | 15 |
| cash | 30.7 | 15 |
| Total Net Leverage Ratio | 1.85 | 30 |
| Mesa Laboratories, published 2026-06-03, period FY2026 | ||
| working capital | $44.4 million | 14 |
| revolver outstanding | $84.5 million | 14 |
| non-US sales percentage | 45% | 14 |
| GKE seller settlement April | $9,555 | 14 |
| GKE acquisition total consideration | $87,187 | 14 |
| Dialyguard gross profit margin percentage | one-third | 14 |
| Dialyguard Calibration Solutions revenue percentage | approximately 30% | 14 |
| Clinical Genomics single customer revenue concentration | approximately 20% | 14 |
| Clinical Genomics consumables revenue percentage | approximately 80% | 14 |
| China Sales Percentage | approximately 8% | 14 |
| Cash Provided by Operating Activities | 42,831 | 14 |
| Cash on Hand | $26.9 million | 14 |
| Biopharmaceutical Development Hardware Revenue Percentage | Approximately 40% | 14 |
| Biopharmaceutical Development Consumables Revenue Percentage | about 35% | 14 |
| Backlog Sterilization Disinfection | decreased by approximately $1.2 million | 14 |
| Backlog March 31 | approximately $33.6 million | 14 |
| Backlog March 31 | $43.2 million | 14 |
| Mesa Laboratories, published 2026-05-27, period FY2026 | ||
| Total Net Leverage Ratio | 2.11 | 29 |
| AOI per share | 10.72 | 29 |
| AOI per share - diluted | 2.76 | 29 |
| AOI excluding unusual items per share | 11.41 | 29 |
| AOI excluding unusual items per share - diluted | 3.30 | 29 |
| Mesa Laboratories, published 2026-02-03, period 2026-Q3 | ||
| Working Capital | 51.2 million | 13 |
| Total Net Leverage Ratio | 2.62 | 28 |
| Revolver Available | 26.7 million | 13 |
| Cash | 29.0 million | 13 |
| Mesa Laboratories, published 2025-11-06, period 2026-Q2 | ||
| working capital | 49.1 million | 12 |
| revolver outstanding | 106.0 million | 12 |
| Quarterly Dividend per Share | 0.16 | 12 |
| Cash on Hand | 20.4 million | 12 |
| Bookings | approximately 5% greater than revenues | 12 |
| Total Net Leverage Ratio | 3.02 | 27 |
| Mesa Laboratories, published 2025-08-05, period 2026-Q1 | ||
| Total Net Leverage Ratio | 3.16 | 26 |
| Dividends per Share | 0.16 | 11 |
| Mesa Laboratories, published 2025-05-28, period FY2025 | ||
| working capital | $(61.3) million | 10 |
| Revolver Available | 115.0 million | 10 |
| Convertible Notes Outstanding | 97.5 million | 10 |
| Cash and Cash Equivalents | 27.3 million | 10 |
| Backlog | 43.2 million | 10 |
| Recurring revenue mix (FY25) | ~75% | 25 |
| Past due backlog change (Q4 vs Q3) | 27% decrease | 25 |
| Past due backlog | approximately $2,000 higher | 25 |
| Operating income margin (Q4) | 2.4% | 25 |
| Operating income margin (FY) | 6.8% | 25 |
| Net Leverage Ratio | 3.01 | 25 |
| Free cash flow | 42,559 | 25 |
| Core organic revenues growth (Q4) | 6.3% | 25 |
| Core organic revenues growth (FY) | 5.0% | 25 |
| Cash flows from operations | 46,808 | 25 |
| AOI as percentage of revenues (Q4) | 19.7% | 25 |
| AOI as percentage of revenues (FY) | 23.5% | 25 |
| Mesa Laboratories, published 2025-02-04, period 2025-Q3 | ||
| Total Net Leverage Ratio | 3.20 | 24 |
| Sterilization and Disinfection Control Organic Growth 9M Prior | 1.0% | 9 |
| Sterilization and Disinfection Control Organic Growth 9M | 2.9% | 9 |
| Sterilization and Disinfection Control organic growth 3m prior | (4.8%) | 9 |
| Sterilization and Disinfection Control organic growth 3m | 7.8% | 9 |
| Clinical Genomics organic growth 9m prior | (14.6%) | 9 |
| Clinical Genomics organic growth 9m | (14.2%) | 9 |
| Clinical Genomics organic growth 3m prior | (19.5%) | 9 |
| Clinical Genomics organic growth 3m | 1.0% | 9 |
| Calibration Solutions organic growth 9m prior | 8.6% | 9 |
| Calibration Solutions organic growth 9m | 10.1% | 9 |
| Calibration Solutions organic growth 3m prior | 12.9% | 9 |
| Calibration Solutions organic growth 3m | 18.7% | 9 |
| Biopharmaceutical Development organic growth 9m prior | (18.2%) | 9 |
| Biopharmaceutical Development organic growth 9m | 26.6% | 9 |
| Biopharmaceutical Development organic growth 3m prior | (19.1%) | 9 |
| Biopharmaceutical Development organic growth 3m | 29.8% | 9 |
| Mesa Laboratories, published 2024-11-07, period 2025-Q2 | ||
| working capital | (45,252) | 8 |
| cash and equivalents | 24,337 | 8 |
| Net Leverage Ratio | 3.26 | 23 |
| AOI margin excluding unusual items pct | 24.8% | 23 |
| Mesa Laboratories, published 2024-08-05, period 2025-Q1 | ||
| working capital | 51,825 | 7 |
| Revolver Available | 83,000 | 7 |
| cash and equivalents | 28,472 | 7 |
| Total Net Leverage Ratio | 3.41 | 22 |
| Gross profit percentage | 64.0 | 22 |
| Mesa Laboratories, published 2024-06-28, period FY2024 | ||
| working capital | $65,040 | 6 |
| credit facility outstanding | $50,500 | 6 |
| convertible senior notes outstanding | $172,500 | 6 |
| Cash and Cash Equivalents | $28,214 | 6 |
| Mesa Laboratories, published 2024-06-05, period FY2024 | ||
| Revenues | 58,904 | 21 |
| Operating loss | (271,284) | 21 |
| Net loss | (254,583) | 21 |
| Loss per diluted share | (47.20) | 21 |
| AOI per share - diluted | 2.29 | 21 |
| AOI excluding unusual items per share - diluted | 2.77 | 21 |
| Mesa Laboratories, published 2024-02-05, period 2024-Q3 | ||
| working capital | 74,172 | 5 |
| cash and equivalents | 28,224 | 5 |
| Adjusted operating income excluding unusual items as a percentage of revenues | 22.4% | 20 |
| Mesa Laboratories, published 2023-11-06, period 2024-Q2 | ||
| working capital Sept 30 | 77,846 | 4 |
| working capital March 31 | 75,616 | 4 |
| stock-based compensation expense | 6,151 | 4 |
| Reduction in force costs | 350 | 4 |
| Open Market Sale Agreement capacity | 150,000 | 4 |
| Notes aggregate principal | 172,500 | 4 |
| GKE acquisition one-time costs | 505 | 4 |
| Expected annual savings from reduction in force | 2,000 | 4 |
| Expected annual interest expense, $65,000 borrowing | 4,485 | 4 |
| Credit Facility borrowed Oct | 65,000 | 4 |
| Credit Facility amended amount | 125,000 | 4 |
| Core organic revenue growth | (10.1)% | 19 |
| Core organic revenue growth | (4.6)% | 19 |
| Cash and cash equivalents, Sept 30 | 35,617 | 4 |
| Cash and cash equivalents, Mar 31 | 32,910 | 4 |
| AOI excluding unusual items per diluted share | 1.91 | 19 |
| Mesa Laboratories, published 2023-08-03, period 2024-Q1 | ||
| Working capital | 75,616 | 3 |
| Working capital | 75,682 | 3 |
| Stockholders' equity | 387,719 | 18 |
| Revenues | 50,645 | 18 |
| Quarterly dividend per share | 0.16 | 3 |
| Operating loss | (664) | 18 |
| Open purchase order commitments | 17,347 | 3 |
| Open Market Sale Agreement capacity | 150,000 | 3 |
| Net loss | (549) | 18 |
| Loss per share (diluted) | (0.10) | 18 |
| Credit Facility outstanding | 5,000 | 3 |
| Convertible Notes outstanding | 172,500 | 3 |
| Contingent consideration for Belyntic patents | 1,500 | 3 |
| Cash and cash equivalents | 32,910 | 3 |
| Cash and cash equivalents | 32,376 | 3 |
| Cash and cash equivalents | 32,376 | 18 |
| Adjusted operating income per share (diluted) | 1.77 | 18 |
Mesa Laboratories Development
A condensed summary of Mesa Laboratories per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. NadirAlpha methodology
FY2027: Mesa Laboratories
Mesa Laboratories opened fiscal 2027 with first-quarter revenue of 60.1 million, a 1.0% increase year over year, with Calibration Solutions and Biopharmaceutical Development contributing growth that was partially offset by lower Sterilization and Disinfection Control revenue 15. Operating income rose to 7 million, reflecting operating efficiencies and cost-containment initiatives, while gross profit margin expanded 290 basis points to 64.9%, primarily from lower third-party contracted labor costs and supply chain efficiency improvements 15. Cash flows from operating activities were 14.7 million, compared with $1.9 million in the prior-year period, driven by improved collections and operating performance 15. Mesa Laboratories repaid $8.7 million of debt and reduced its total net leverage ratio to 1.85, below its stated 2.0 target 30. New CEO Siddhartha Kadia had joined approximately 100 days prior to the first-quarter report; full-year guidance was expected to be provided in November 30.
FY2026: Mesa Laboratories
Mesa Laboratories FY2026 revenues grew 3.4% to $249.1 million, with organic growth of 3.4% and core organic growth of 1.2%, driven primarily by the Sterilization and Disinfection Control division's 8.7% organic revenue increase and Calibration Solutions' 3.5% organic gain 29 14. Operating income increased 13.3% to $18.5 million and non-GAAP adjusted operating income expanded 200 basis points to 25.5% of revenues at $63.5 million 29. Net income recovered to $6.7 million versus a prior-year loss of $1.9 million, supported by $39.6 million of free cash flow and a reduction in the Total Net Leverage Ratio to 2.11 at fiscal year-end 29 14. Clinical Genomics remained a headwind throughout the year as China revenues contracted 57.4% amid macroeconomic and regulatory uncertainty, partially offset by 9.1% growth outside China 29. CEO Siddhartha Kadia was appointed effective April 2026 and initiated a 100-day business review 29.
FY2025: Mesa Laboratories
Mesa Laboratories reported FY2025 consolidated revenues of $241.0 million, an increase of 11.5% from $216.2 million in fiscal year 2024, with core organic growth of 5.0% and the GKE acquisition contributing $24.8 million of inorganic revenues 10. Biopharmaceutical Development achieved 19.7% organic revenue growth, benefiting from recovered capital equipment demand in the biopharmaceutical vertical, while Clinical Genomics organic revenues declined 10.5% due to headwinds in China and U.S. regulatory constraints on lab-developed tests 10. Operating income improved to $16.3 million in FY2025 from an operating loss in FY2024 that included a $274.5 million impairment charge; on an adjusted basis, operating income grew 12.3% for the full year 25. Free cash flow of $42.6 million enabled ongoing debt repayments, reducing the Net Leverage Ratio to 3.01 by fiscal year-end 25. The GKE acquisition was fully integrated within nine months and exceeded initial revenue and profitability commitments, while all four divisions delivered core organic revenue growth in Q4 FY2025 25.
FY2024: Mesa Laboratories
Mesa Laboratories Inc. reported FY2024 total revenues of $216.2 million, a 1.3% decrease year-over-year, with core organic revenues declining 5.4% as sustained softening in life sciences capital equipment markets and the prior-year loss of major Clinical Genomics customer Sema4 weighed on results throughout the year (6, 25). The acquisition of GKE GmbH and its China entity, completed in October and December 2023 respectively, contributed $9.3 million to the Sterilization and Disinfection Control division and partially offset organic declines (21). In Q4 FY2024 the company recorded $274.5 million in non-cash goodwill and long-lived asset impairment charges against the Clinical Genomics ($236.4 million) and Biopharmaceutical Development ($38.2 million) divisions, driving a GAAP full-year operating loss of $272.1 million and net loss of $254.2 million (21, 6). On an adjusted non-GAAP basis, adjusted operating income was $46.0 million for FY2024, while free cash flow of $41.6 million reflected improved working capital management versus the prior year (25). Mesa Laboratories refinanced its credit facility extending maturity to April 2029, repurchased $75.0 million of its 2025 Convertible Notes, and restructured the Clinical Genomics division under new leadership (6).
FY2023: Mesa Laboratories
Mesa Laboratories reported fiscal year 2023 revenues of $219.1 million, an 18.8% increase versus fiscal year 2022, primarily driven by the Agena Bioscience acquisition completed in October 2021; core organic revenue growth was 5.2% 17. Full-year GAAP operating income declined 29.4% to $3.3 million and net income fell 50% to $0.9 million as higher operating expenses from the Agena acquisition weighed on reported results, while adjusted operating income was $49.0 million 6. The Clinical Genomics division faced an approximately $8.2 million annual revenue headwind after Sema4 Holdings notified the company of its intent to exit reproductive health screening; excluding this impact, core organic growth would have been approximately 15% for the full year 17. Sterilization and Disinfection Control achieved core organic growth of 12.2% for the year, while Calibration Solutions revenues declined 4% due to raw materials supply constraints that began abating in the fourth quarter 2. Free cash flow totaled $23.4 million for the year, and material weaknesses were identified in internal controls over fair value and goodwill impairment assessments as of March 31, 2023 2.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
All original documents NadirAlpha used for this report on Mesa Laboratories stock: quarterly and annual reports, earnings releases and investor relations documents, sorted by publication, the document type is the link. NadirAlpha methodology
Older sources (+16)
| # | Document type | Published |
|---|---|---|
| #202 | 10-K annual report | 2016-06-06 |
| #205 | 10-K annual report | 2016-06-06 |
| #201 | 10-Q quarterly report | 2016-11-07 |
| #206 | 10-K annual report | 2017-06-07 |
| #203 | 10-Q quarterly report | 2017-08-01 |
| #204 | 10-Q quarterly report | 2017-11-06 |
| #210 | 10-K annual report | 2019-06-03 |
| #207 | 10-Q quarterly report | 2019-07-30 |
| #208 | 10-Q quarterly report | 2019-11-06 |
| #209 | 10-Q quarterly report | 2020-02-10 |
| #214 | 10-K annual report | 2020-06-01 |
| #211 | 10-Q quarterly report | 2020-08-06 |
| #212 | 10-Q quarterly report | 2020-11-05 |
| #213 | 10-Q quarterly report | 2021-02-03 |
| #215 | 10-Q quarterly report | 2021-08-05 |
| #216 | 10-Q quarterly report | 2021-11-04 |
Mesa Laboratories Stock FAQ
Which additional key figures does Mesa Laboratories report?
As reported for Q1 FY2027 (Apr to Jun 2026): Total Net Leverage Ratio. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Sterilization and Disinfection Control, Calibration Solutions, Biopharmaceutical Development, Clinical Genomics.
Does Mesa Laboratories pay a dividend?
The filings report on the dividend; most recent entry: dividend per share 0.16 (2027-Q1) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Mesa Laboratories?
NadirAlpha links all 46 original filings used (SEC filings) in the sources chapter: quarterly report, earnings release, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.